Healthcare
ReNeuron Group plc(RNUGF)
Live Price
Offline$0.0011
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 12, 2026
- Market Cap
- —
- Revenue Growth
- +31.5%
- EPS Growth
- +44.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars · Jun 20, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ReNeuron Group plc (RNUGF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +31.5%, EPS growth of +44.3%, a dividend yield of 0.0%. What stands out right now is revenue +31.5%, EPS +44.3%, free cash flow +0.1% with operating margin -1342.5% and ROIC -105.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RNUGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+31.5% vs +7.6% peer median
Operating Margin
Below sector median
-1342.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +31.5% and EPS at +44.3%, with operating margin around -1342.5%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNUGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNUGF Max Drawdown
-99.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RNUGF and SPY.
Company Overview
ReNeuron Group plc
Other OTC
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
- Leadership
- Iain Gladstone Ross
- IPO Date
- Apr 12, 2007
- Employees
- 26
- Street Address
- Pencoed Business Park
- Mailing
- Pencoed, CF35 5HY
- Region
- Pencoed, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 3819 8400
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.9
- Price/Sales
- 0.1
- Price/Book
- 0.0
Growth
- Revenue
- +31.5%
- EPS
- +44.3%
- Free Cash Flow
- +0.1%
Profitability
- Gross Margin
- -742.1%
- Operating Margin
- -1342.5%
- Net Margin
- -1020.4%
- ROE
- -72.4%
- ROIC
- -105.5%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 2.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.